Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Pharm Res
2008 Mar 01;253:639-46. doi: 10.1007/s11095-007-9401-6.
Show Gene links
Show Anatomy links
Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers.
Sato M
,
Iwanaga T
,
Mamada H
,
Ogihara T
,
Yabuuchi H
,
Maeda T
,
Tamai I
.
Abstract
To examine the mechanisms of the alteration of serum uric acid level by angiotensin II receptor blockers (ARBs), the effects of ARBs on renal uric acid transporters, including OAT1, OAT3, OAT4, and MRP4, were evaluated. Uptakes of uric acid by OAT1-expressing Flp293 cells, by Xenopus oocytes expressing OAT3 or OAT4, and by membrane vesicles from Sf9 cells expressing MRP4 were evaluated in the presence or absence of ARBs. All ARBs inhibited uptake of uric acid or estrone-3-sulfate by OAT1, OAT3 and OAT4 in concentration dependent manners. Among them, the IC50 values of valsartan, olmesartan and pratosartan for OAT3 were comparable to clinically observed unbound maximum plasma concentration of ARBs. Candesartan, losartan, and telmisartan inhibited ATP-dependent uptake of uric acid by MRP4 at 10 microM. The IC50 value of losartan for MRP4 was comparable to the estimated kidneytissue concentration of losartan. No ARBs showed trans-stimulatory effects on the uptake of estrone-3-sulfate by OAT4. Valsartan, olmesartan, and pratosartan could inhibit the OAT3-mediated uric acid secretion in clinical situations. Furthermore losartan could inhibit ATP-dependent uric acid secretion by MRP4. These effects may explain partially the alteration of serum uric acid level by ARBs.
Alderman,
Serum uric acid and cardiovascular events in successfully treated hypertensive patients.
1999, Pubmed
Alderman,
Serum uric acid and cardiovascular events in successfully treated hypertensive patients.
1999,
Pubmed
Burnier,
Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects.
1993,
Pubmed
Cha,
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.
2001,
Pubmed
,
Xenbase
Elliott,
Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial.
2001,
Pubmed
Enomoto,
Molecular identification of a renal urate anion exchanger that regulates blood urate levels.
2002,
Pubmed
,
Xenbase
Fauvel,
Effects of losartan on renal function in patients with essential hypertension.
1996,
Pubmed
Hagos,
Human renal organic anion transporter 4 operates as an asymmetric urate transporter.
2007,
Pubmed
,
Xenbase
Hediger,
Molecular physiology of urate transport.
2005,
Pubmed
Hosoyamada,
Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney.
1999,
Pubmed
,
Xenbase
Ichida,
Urate transport via human PAH transporter hOAT1 and its gene structure.
2003,
Pubmed
Ishiguro,
Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney.
2005,
Pubmed
,
Xenbase
Iwanaga,
Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.
2007,
Pubmed
,
Xenbase
Iwanaga,
Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone.
2005,
Pubmed
,
Xenbase
Liman,
Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs.
1992,
Pubmed
,
Xenbase
Manolis,
Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators.
2000,
Pubmed
Nakashima,
Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects.
1992,
Pubmed
Ohashi,
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
1999,
Pubmed
Rius,
Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.
2003,
Pubmed
Rundles,
The development of allopurinol.
1985,
Pubmed
Tsuda-Tsukimoto,
Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035.
2006,
Pubmed
,
Xenbase
Tsuji,
[Tissue distribution of the multidrug-resistance gene product P-glycoprotein and its physiological function].
1997,
Pubmed
Uchino,
p-aminohippuric acid transport at renal apical membrane mediated by human inorganic phosphate transporter NPT1.
2000,
Pubmed
Van Aubel,
Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites.
2005,
Pubmed
Verdecchia,
Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study.
2000,
Pubmed
Yamashita,
Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4.
2006,
Pubmed
